secwatch.observer — SEC 8-K summary
======================================

Issuer:     RVL Pharmaceuticals plc (—)
CIK:        0001739426
Form:       8-K
Filed at:   2023-10-20T23:59:59+00:00
Accession:  0001104659-23-110536
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 1.03, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RVL Pharma subsidiaries file Chapter 11; $17.5M DIP financing approved
----------------------------------------------------------------------

- RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals Inc. and RVL Pharmacy LLC filed Chapter 11 on Oct 12, 2023.
- Bankruptcy Court approved interim DIP financing on Oct 13; $17.5M facility led by Athyrium, $7.5M drawn immediately.
- Parent RVL PLC not in bankruptcy; shares expected to be cancelled upon winddown with no recovery for shareholders.
- DIP loan has 9.50% margin, multi-draw terms, minimum liquidity covenant of $2.5M, and 7-week operating budget.
- Trading in RVLP ordinary shares is highly speculative; company urges extreme caution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739426/000110465923110536/0001104659-23-110536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739426/000110465923110536/tm2328848d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-110536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer